Xarelto is a prescription medication used to prevent certain types of blood clots and strokes. Xarelto can be used in people who are having hip or knee replacement surgery, and for people with an irregular heart rhythm.
Xarelto , a "blood thinner", belongs to a group of drugs called factor Xa inhibitors. Factor Xa is an enzyme required for blood to clot. Xarelto inhibits factor Xa, slowing down blood clot formation.
This medication comes in tablet form and is usually taken once daily, with or without food. For people taking it for atrial fibrillation (irregular heart rhythm), Xarelto is taken once daily with the evening meal.
Common side effects include itching, muscle spasms, and bleeding.
WARNINGS: (A) DISCONTINUING XARELTO IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION INCREASES RISK OF STROKE, (B) SPINAL/EPIDURAL HEMATOMA
A. DISCONTINUING XARELTO IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Discontinuing Xarelto places patients at an increased risk of thrombotic events. An increased rate of stroke was observed following Xarelto discontinuation in clinical trials in atrial fibrillation patients. If anticoagulation with Xarelto must be discontinued for a reason other than pathological bleeding, consider administering another anticoagulant.
B. SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas have occurred in patients treated with Xarelto who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
- use of indwelling epidural catheters
- concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.
